Abbreviations & Acronyms ANC = absolute neutrophil count BEP = bleomycin, etoposide and cisplatin BMI = body mass index BUN = blood urea nitrogen CI = confidence interval eGFR = estimated glomerular filtration rate FN = febrile neutropenia G-CSF = granulocyte colony-stimulating factor GCT = germ cell tumor IGCCC = International Germ Cell Consensus Classification mGCTs = metastatic germ cell tumors PS = performance status TIP = paclitaxel, ifosfamide and cisplatin Objectives: To identify clinical features and predictive factors of febrile neutropenia in Japanese patients with metastatic germ cell tumors undergoing cytotoxic chemotherapy. Methods: Between April 2007 and May 2016, 86 consecutive Japanese patients with metastatic germ cell tumors were treated with cisplatin-based combination chemotherapy, including bleomycin, etoposide and cisplatin, and paclitaxel, ifosfamide and cisplatin. A total of 378 chemotherapy cycles administered for these 86 patients were retrospectively analyzed. Results: During the 378 cycles, consisting of 212 for bleomycin, etoposide and cisplatin, and 166 for paclitaxel, ifosfamide and cisplatin, 81 episodes of febrile neutropenia (21.4%) developed in 34 patients (39.5%). Multivariate logistic regression analysis showed that low estimated glomerular filtration rate and albumin levels were independent risk factors for the development of febrile neutropenia. Furthermore, a significant difference in the incidence of febrile neutropenia was noted according to positive numbers of these two independent risk factors; that is, febrile neutropenia occurred in 13 of 171 courses in patients negative for any risk factors (7.6%), 44 of 155 courses in those positive for a single risk factor (28.4%) and 24 of 52 courses in those positive for two risk factors (46.2%). Conclusions: The incidence of febrile neutropenia in Japanese metastatic germ cell tumor patients receiving cisplatin-based combination chemotherapy appears to be higher than reported previously by studies in Western countries. When carrying out cytotoxic chemotherapy, special attention should be paid to patients with low estimated glomerular filtration rate and/or albumin levels considering the high probability of febrile neutropenia.
Introduction
GCTs are relatively rare, accounting for only 1% of all malignant diseases in men, but they represent the most common solid tumor in males between 15 and 35 years-of-age. 1 The introduction of cisplatin-based combination chemotherapy in the late 1970s resulted in a marked improvement in the prognosis of patients with mGCTs and, in fact, overall cure rates currently exceed 80%. 2 To maintain the highest chance of cure, a number of studies have shown that chemotherapy should be given without dose reductions or treatment delays; therefore, very high-level expertise associated with cytotoxic chemotherapy is required of physicians who treat patients with mGCTs. 3 FN is a common and serious clinical consequence of myelosuppressive chemotherapy. With major advances in prevention and treatment with respect to cytotoxic chemotherapy, mortality from FN has decreased steadily; however, FN often results in dose reduction and/or treatment delay in subsequent chemotherapeutic cycles, which potentially compromise therapeutic efficacies. 4 Although several guidelines are now available for the management of FN, it might be important to recognize that they are based on a literature review of studies across a wide variety of malignant tumors and, thus, are not specific to mGCTs. [5] [6] [7] Accordingly, it is necessary for the management of FN in mGCT patients to consider the characteristics of this malignancy as different from others as follows: GCTs are likely to develop in a younger population with a favorable performance status, whereas chemotherapeutic regimens applied to patients with mGCTs are intensive and require inpatient clinical care. In addition, the incidence of FN in patients with GCTs was reported to be greatest among the solid malignant tumors studied, suggesting that it is a clinically important issue to address features associated with FN in patients with mGCTs receiving cytotoxic chemotherapy. 8 Considering these findings, we retrospectively reviewed the clinical outcomes of cytotoxic chemotherapy in Japanese mGCT patients focusing on FN, in order to identify useful predictors of this adverse event in a routine clinical setting.
Methods
Between April 2007 and May 2016, 86 Japanese patients with mGCT were treated with cisplatin-based combination chemotherapy at Seirei Mikatabara Hospital, Hamamatsu; Kobe University Hospital, Kobe; and Hamamatsu University Hospital, Hamamatsu, Japan. In total, 396 chemotherapeutic cycles were administered to these 86 patients, and 12 cycles were excluded from the final analyses because of the dose reduction and six cycles were excluded because of the incomplete date. Thus, a total of 378 consecutive cycles administered to these 86 patients were included in the present study. The study design of this series was approved by the research ethics committee of the Kobe University Graduate School of Medicine, and informed consent for carrying out the present study was obtained from all of the included patients.
As previously reported, our therapeutic strategies for mGCTs during the study period of this series were as follows. (i) As induction chemotherapy, four cycles of BEP were administered to good-prognosis GCT patients according to the IGCCC; however, when tumor markers remained abnormal after two cycles of BEP, ≥2 cycles of TIP were added for these patients. 9 (ii) The early incorporation of TIP into induction chemotherapy was also applied for patients who were categorized into intermediate-or poor-prognosis GCT groups according to the IGCCC; that is, these patients received two cycles of BEP followed by ≥2 cycles of TIP, as previously described. 9 (iii) When patients were judged to show refractory or relapsed disease after the induction chemotherapy described above, they subsequently received TIP until tumor markers had normalized. The regimens of the two chemotherapies described above were as follows. In the present study, we defined FN as a single axillary temperature of ≥37.5°C with an ANC <500 cells/mm 3 or with a predicted decrease to <500 cells/mm 3 within 48 h in accordance with the recommendation by the Japanese Society of Medical Oncology. 10 As a rule, G-CSF was given, when ANC was <500 cells/mm 3 , irrespective of the presence of fever. Prophylactic antibiotics were not routinely used; however, carbapenem or a fourth-generation cephalosporin was used as the initial antimicrobial immediately after detecting FN. Red blood cell transfusion was carried out in patients with clinical anemic symptoms, whereas platelet transfusion was given to patients with a platelet count <20 000/m 3 . In the present study, treatment delay was also defined as any cycle being delivered more than 3 days later than planned. All laboratory tests were carried out on the first day of each cycle of chemotherapy.
All statistical analyses were carried out using Statview 5.0 software (Abacus Concepts, Berkeley, CA, USA), and Pvalues <0.05 were considered significant. Logistic regression analysis was used to determine the association between several parameters and the incidence of FN in each chemotherapy course. Differences in the probability of FN among three groups were analyzed by the v 2 -test.
Results
A total of 66 patients (76.7%) achieved the normalization of serum tumor markers after a course of treatment. Table 1 summarizes the clinicopathological characteristics of the 86 patients included in the present study. As shown in Table 2 , the number of chemotherapy cycles given to these 86 patients ranged from 4 to 9 (median 5). In this study, all 86 patients were initially treated with two to four cycles of BEP (median 3). Of these, 45 patients (52.3%) then received a median of two to seven cycles of TIP (median 3). A total of 76 patients (88.4%) and 34 patients (42.0%) received G-CSF and antibiotics at least once during their therapeutic courses, respectively. As a result, a total of 378 cycles of anticancer chemotherapy, consisting of 212 cycles of BEP and 166 cycles of TIP, were analyzed in this study. As for the incidence of FN, no significant difference was noted between BEP and TIP regimens. In a total of 378 chemotherapy cycles, 81 episodes of FN (21.4%) occurred in 34 patients (42.0%), and of these, 29 FN episodes (35.8%) in 22 (25.6%) patients resulted in the delay of subsequent chemotherapy. FN was observed in 23 patients (34.9%) out of 66 patients who achieved the normalization of serum tumor markers after a course of treatment; therefore, there was no correlation between the efficacy of chemotherapy and the delay as a result of FN in the present study. Table 3 shows the logistic regression analysis of predictive factors associated with the development of FN in each chemotherapy course. Univariate analysis identified the IGCCC (intermediate-or poor-risk), number of previous chemotherapies, hemoglobin, platelet, BUN, eGFR and albumin as significant risk factors of the occurrence of FN. Of these, eGFR and albumin appeared to be independent risk factors for the development of FN on multivariate analysis. Furthermore, a significant difference was observed in the proportion of the development of FN in each chemotherapy course according to positive numbers of these two independent predictive factors (P < 0.001); that is, FN occurred in 13 of 171 courses in patients negative for all risk factors (7.6%), 44 of 155 courses in those positive for a single risk factor (28.4%) and 24 of 52 courses in those positive for two risk factors (46.2%), as shown in Table 4 .
Discussion
Despite major advances in the management of adverse events associated with cytotoxic chemotherapy, FN remains one of the most serious complications in patients treated with chemotherapy. Furthermore, FN is a major cause of the compromised efficacy of chemotherapy, because of the requirements of a delay and dose reduction of the chemotherapeutic regimen, resulting in unfavorable effects on the prognostic outcomes, particularly those in patients receiving chemotherapy with a curative intent. A number of studies, therefore, have tried to identify reliable risk factors for chemotherapyinduced FN in various types of malignancy. 4 Based on the findings of these studies, current guidelines advocate that both treatment intent and patient risk factors should be considered when determining the overall risk of FN and recommend risk-adapted treatments, such as the prophylactic use of G-CSF and/or broad spectrum antibiotics. 5, 6 Albeit just a few reports have focused on chemotherapyinduced FN in patients with mGCT, and diverse incidences of FN have been documented. For example, Counsell et al.
reported that World Health Organization grade 3/4 neutropenia and FN were observed in 56% and 11% of the courses of anticancer chemotherapy for mGCT, respectively.
11 Whereas Cullen et al. previously assessed the incidences of FN in various cancers, and found that FN most frequently occurred in GCT patients, accounting for 27.9%. 8 Furthermore, the majority of information with respect to FN in mGCT patients undergoing cytotoxic chemotherapy were derived from clinical trials. Considering these findings, we retrospectively assessed the clinical outcomes of cytotoxic chemotherapy carried out for Japanese mGCT patients in the routine clinical setting in order to precisely characterize FN developing during the courses of chemotherapy in this cohort of patients.
In the present study, the incidence of FN was 39.5%, which was higher than in previous reports. 8, 11, 12 Despite the Japanese FN guidelines recommended when the probability of FN is >20%, no primary prophylactic use of G-CSF and/ or antibiotics could also result in a high incidence of FN in this series. Although convincing evidence suggests that the prophylactic use of G-CSF and/or broad spectrum antibiotics can reduce FN events in patients receiving cytotoxic agents, there is a marked diversity in the strategies regarding the prophylactic use of these agents because of the high risk of secondary myelodysplastic syndromes/acute myeloid leukemia by G-CSF in a high-dose setting, as well as the frequent emergence of resistance to antibiotics. 13, 14 In fact, the Japanese guidelines for the proper use of G-CSF did not recommend primary prophylaxis for complications of neutropenia with G-CSF, if the risk of FN is <20%. 15 Considering these findings, primary prophylactic G-CSF and/or antibiotics, which might be justified in patients at high risk of FN, were not used in the present study. Taken together, as strongly recommended by major guidelines, the management of FN in cancer patients receiving chemotherapy should be carried out according to the risk of FN in each patient.
To date, several factors have been shown to increase the risk of chemotherapy-induced FN in patients with malignant tumors, such as an older age, poor performance status and concomitant severe complications. 8 In general, however, patients with mGCT are younger, with a better performance status and few comorbidities; hence, it is of interest to evaluate the impacts of several parameters on the probability of FN in mGCT patients. In this series, multivariate logistic regression analysis identified low eGFR and albumin levels as independent risk factors for the development of FN. Lyman et al. carried out a prospective study consisting of 3760 patients with common solid tumors or malignant lymphoma, and showed that along with several clinical factors, renal function was independently associated with the development of FN. 16 Albumin levels was also detected as a risk factor for FN among patients with gynecological cancer and non-Hodgkin lymphoma. 17, 18 Low albumin levels are usually associated with a catabolic state, which results in immunosuppression. 19 Collectively, both the renal function and serum albumin are regarded as parameters reflecting immune system function; 20, 21 thus, the value of these two factors to predict the development of FN could be explained, at least in part, by their involvement in immunological activity. Here, we would like to emphasize several limitations of the present study. First, this was a retrospective study with a small sample size; therefore, it is difficult to draw definitive conclusions. Second, the proportion of patients treated with four cycles of BEP, which is regarded as a standard induction therapy for advanced GCT patients, was relatively low in this series. In addition, early incorporation of TIP into induction therapy for patients with intermediate-or poor-risk mGCT patients, and four cycles of BEP administration for goodprognosis patients are not according to the international standard, and might be overtreatment in some cases. Third, the definition of FN varies among different studies, which makes it difficult to compare the present findings with those in previous studies. Finally, despite being a potentially important issue, appropriate medical interventions for maintaining the renal function and/or nutrition in patients receiving cytotoxic chemotherapy remain controversial at present because of the lack of data with a high-evidence level.
In conclusion, the incidence of FN in Japanese mGCT patients receiving cisplatin-based combination chemotherapy appeared to be higher than in previous reports in Western countries. Furthermore, multivariate analysis identified the eGFR and albumin levels as independent predictive factors for the development of FN in these patients. Accordingly, close observation is required for GCT patients with low eGFR and/or albumin levels on each cycle of chemotherapy. 
